Cytokines and microRNAs in SARS-CoV-2: What do we know?

(2022) Cytokines and microRNAs in SARS-CoV-2: What do we know? Molecular therapy. Nucleic acids. pp. 219-242. ISSN 2162-2531 (Print) 2162-2531 (Electronic) 2162-2531 (Linking)

Full text not available from this repository.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of pro-inflammatory cytokines in patients suffering from severe COVID-19, leading to the development of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and even mortality. Understanding the pathophysiology of COVID-19 can be helpful for the treatment of patients. Evidence suggests that the levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-1 and IL-6 are dramatically different between mild and severe patients, so they may be important contributors to the cytokine storm. Several serum markers can be predictors for the cytokine storm. This review discusses the cytokines involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, focusing on interferons (IFNs) and ILs, and whether they can be used in COVID-19 treatment. Moreover, we highlight several microRNAs that are involved in these cytokines and their role in the cytokine storm caused by COVID-19.

Item Type: Article
Keywords: Covid-19 Janus kinases NF-kappaB SARS-CoV-2 STAT transcription factors cytokines interferons interleukins microRNAs advisory boards for Transdermal Cap Inc (Cleveland, OH), Hologenix Inc (Santa Monica, CA), Vielight (Toronto, Canada), and JOOVV Inc (Minneapolis St Paul MN) consulting for USHIO Corp (Japan) and Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, Germany). The other authors declare no competing interests.
Page Range: pp. 219-242
Journal or Publication Title: Molecular therapy. Nucleic acids
Journal Index: Pubmed
Volume: 29
Identification Number: https://doi.org/10.1016/j.omtn.2022.06.017
ISSN: 2162-2531 (Print) 2162-2531 (Electronic) 2162-2531 (Linking)
Depositing User: خانم ناهید ضیائی
URI: http://eprints.mui.ac.ir/id/eprint/24538

Actions (login required)

View Item View Item